Elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling
碩士 === 國立陽明大學 === 生物藥學研究所 === 103 === Lung cancer is the leading cause of cancer death around the world. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. In the present clinical treatment, patients receive cisplatin plus gemcitabine or pemetrexed for lung squamo...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | en_US |
Published: |
2015
|
Online Access: | http://ndltd.ncl.edu.tw/handle/02155410213293017670 |
id |
ndltd-TW-103YM005603005 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-103YM0056030052016-08-28T04:12:23Z http://ndltd.ncl.edu.tw/handle/02155410213293017670 Elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling 藉由微陣列晶片資料評估老藥在非小細胞肺癌上的新作用 Cheng-Hao Yu 余晟豪 碩士 國立陽明大學 生物藥學研究所 103 Lung cancer is the leading cause of cancer death around the world. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. In the present clinical treatment, patients receive cisplatin plus gemcitabine or pemetrexed for lung squamous carcinoma or lung adenocarcinoma with EGFR wild-type. However, NSCLC patients resistant to chemotherapeutic treatment might be due to cancer stem cells theory. Therefore, it is important to find potential drugs to kill CSCs and to overcome drug resistance and. From connectivity map, phenothiazine derivatives were revealed to have potential to reverse CSCs gene signature. But the effects of drug P in NSCLC are still unclear. In the present study, gene signatures of drug P in NSCLC cell lines via L1000 microarray were used to query CPDB and LINCS database to figure out its inhibitory effects. From bioinformatics analysis, drug P potentially induced cell cycle, autophagy, senescence, and EGFR signaling. These results indicated that drug P inhibited the cell viability of NSCLC parental and spheroid cells, but did not affect the original target, dopamine receptor D2. Drug P also showed inhibitory effects on CSC characteristics and decreased CSC markers in lung cancer spheres. Microarray analysis and microscopy observation showed that dramatic changes in combination with pemetrexed to induce DNA damage. Drug P alone or in combination with various chemo- or target therapy drugs suppressed tumorigenesis in vivo. Taken together, drug P is a potent anti-cancer and anti-cancer stem cell drug in NSCLC, and warrants for clinical trials in the future. Chi-Ying Huang 黃奇英 2015 學位論文 ; thesis 76 en_US |
collection |
NDLTD |
language |
en_US |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 國立陽明大學 === 生物藥學研究所 === 103 === Lung cancer is the leading cause of cancer death around the world. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. In the present clinical treatment, patients receive cisplatin plus gemcitabine or pemetrexed for lung squamous carcinoma or lung adenocarcinoma with EGFR wild-type. However, NSCLC patients resistant to chemotherapeutic treatment might be due to cancer stem cells theory. Therefore, it is important to find potential drugs to kill CSCs and to overcome drug resistance and. From connectivity map, phenothiazine derivatives were revealed to have potential to reverse CSCs gene signature. But the effects of drug P in NSCLC are still unclear. In the present study, gene signatures of drug P in NSCLC cell lines via L1000 microarray were used to query CPDB and LINCS database to figure out its inhibitory effects. From bioinformatics analysis, drug P potentially induced cell cycle, autophagy, senescence, and EGFR signaling. These results indicated that drug P inhibited the cell viability of NSCLC parental and spheroid cells, but did not affect the original target, dopamine receptor D2. Drug P also showed inhibitory effects on CSC characteristics and decreased CSC markers in lung cancer spheres. Microarray analysis and microscopy observation showed that dramatic changes in combination with pemetrexed to induce DNA damage. Drug P alone or in combination with various chemo- or target therapy drugs suppressed tumorigenesis in vivo. Taken together, drug P is a potent anti-cancer and anti-cancer stem cell drug in NSCLC, and warrants for clinical trials in the future.
|
author2 |
Chi-Ying Huang |
author_facet |
Chi-Ying Huang Cheng-Hao Yu 余晟豪 |
author |
Cheng-Hao Yu 余晟豪 |
spellingShingle |
Cheng-Hao Yu 余晟豪 Elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling |
author_sort |
Cheng-Hao Yu |
title |
Elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling |
title_short |
Elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling |
title_full |
Elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling |
title_fullStr |
Elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling |
title_full_unstemmed |
Elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling |
title_sort |
elucidating drug repurposing in non-small cell lung cancer via microarray-based profiling |
publishDate |
2015 |
url |
http://ndltd.ncl.edu.tw/handle/02155410213293017670 |
work_keys_str_mv |
AT chenghaoyu elucidatingdrugrepurposinginnonsmallcelllungcancerviamicroarraybasedprofiling AT yúchéngháo elucidatingdrugrepurposinginnonsmallcelllungcancerviamicroarraybasedprofiling AT chenghaoyu jíyóuwēizhènlièjīngpiànzīliàopínggūlǎoyàozàifēixiǎoxìbāofèiáishàngdexīnzuòyòng AT yúchéngháo jíyóuwēizhènlièjīngpiànzīliàopínggūlǎoyàozàifēixiǎoxìbāofèiáishàngdexīnzuòyòng |
_version_ |
1718380956331540480 |